Joining larger companies in the Metabesity ecosystem are emerging companies that are targeting multiple chronic diseases and longevity based on a variety of approaches. Leaders of emerging companies discuss selected challenges to translating the science into the clinic and into the market, including drug-facing versus consumer-facing business models, the appropriate standards and role of clinical, biomarker and other evidence in regulatory and clinical development and commercialization, and emerging contours of the healthy longevity industry.
Moderator: Ed Saltzman, Executive Chairman at Cello Health BioConsulting, USA
Steven Engle, CEO of Cohbar, Inc., USA
Ben Gibson, Co-founder & CEO of Pano Therapeutics, Inc., USA
Ashish Nimgaonkar MD, President and CEO of Glyscend, USA
Hanadie Yousef, PhD, Co-Founder and CEO of Juvena Therapeutics, USA
Alex Zhavoronkov, PhD, Chief Longevity Officer at Deep Longevity and CEO of InSilico Medicine, USA